Phosphoric Acid

Phosphoric Acid

SCHEMBL262002

O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
SLC34A1 Q06495 1/20 0.46
KDM4E B2RXH2 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
CA1 P00915 2/20 0.35
CA4 P22748 2/20 0.35
CA5A P35218 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
ALOX12 P18054 1/20 0.33
NFKB1 P19838 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL4293475 1.00 LMNA (0.46) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL5923091 1.00 LMNA (0.46) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL35908 1.00 LMNA (0.46) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1311 1.00
Phosphoric Acid SCHEMBL21331079 1.00 LMNA (0.46) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL36070 1.00 LMNA (0.46) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL11382426 0.94
Phosphoric Acid SCHEMBL7525209 0.94 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL156385 0.94 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL20492714 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240352450-A1 Systems and Methods to Determine Nucleic Acid Conformations and Uses Thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-10-24 US claimed
US-20240237636-A1 IMPROVED ADDITIVE SOLUTION FOR WHOLE BLOOD PRESERVATION AND STORAGE UNIVERSITY OF CINCINNATI 2024-07-18 US claimed
US-20240165126-A1 TIANEPTINE OXALATE AND NALOXONE COMBINATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TONIX PHARMACEUTICALS HOLDING CORP. 2024-05-23 US claimed
US-20240066056-A1 Formulations of a Prophylactic Nasal Spray and Methods of Use and Manufacture Thereof NTBY MOSS LLC (US) 2024-02-29 US claimed
EP-4319555-A1 IMPROVED ADDITIVE SOLUTION FOR WHOLE BLOOD PRESERVATION AND STORAGE University of Cincinnati (US) 2024-02-14 EP claimed
CN-115747272-A Synthetic method of vitreous chromogen 闽江学院 2023-03-07 CN claimed
WO-2023028618-A1 SYSTEMS AND METHODS TO DETERMINE NUCLEIC ACID CONFORMATIONS AND USES THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-03-02 WO claimed
WO-2022216955-A1 IMPROVED ADDITIVE SOLUTION FOR WHOLE BLOOD PRESERVATION AND STORAGE UNIVERSITY OF CINCINNATI (US) 2022-10-13 WO claimed
WO-2022197719-A1 TIANEPTINE OXALATE AND NALOXONE COMBINATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TONIX PHARMACEUTICALS HOLDING CORP. (US) 2022-09-22 WO claimed
WO-2022147585-A1 FORMULATIONS OF A PROPHYLACTIC NASAL SPRAY AND METHODS OF USE AND MANUFACTURE THEREOF NTBY MOSS LLC (US) 2022-07-07 WO claimed
CN-104085857-B A kind of novel method preparing high-purity hydrogen acid iodide ZHOU HAIJUN (CN) 2015-12-30 CN claimed
CN-104085857-A New method for preparing high-purity hydroiodic acid ZHOU HAIJUN 2014-10-08 CN claimed
EP-0472639-A4 ACCUMULATION OF DRUGS INTO LIPOSOMES BY A PROTON GRADIENT 1992-07-01 EP claimed
EP-0472639-A1 ACCUMULATION OF DRUGS INTO LIPOSOMES BY A PROTON GRADIENT THE LIPOSOME COMPANY, INC. (US) 1992-03-04 EP claimed
WO-1990014105-A1 ACCUMULATION OF DRUGS INTO LIPOSOMES BY A PROTON GRADIENT THE LIPOSOME COMPANY, INC. (US) 1990-11-29 WO claimed
EP-0175490-A2 Contact lens treatment compositions and their uses SHERMAN LABORATORIES, INC. (US) 1986-03-26 EP claimed
JP-6054659-A None JP disclosed
CN-112274547-B Composition containing silybum marianum extract and fructose-1, 6-bisphosphate and application thereof in liver protection, sobering and fatigue resistance 南京北极光生物科技有限公司 2024-12-27 CN disclosed
US-4178354-A ALKALI METAL ALUMINOSILICOPHOSPHATES KAO SOAP CO., LTD (JP) 1979-12-11 US disclosed
US-3985585-A PROTECTIVE, COLOR RECEPTIVE COATING J. N. TUTTLE, INC. (US) 1976-10-12 US disclosed